title: N-(3-[18F]fluoropropyl)-spiperone: the preferred 18F labeled spiperone analog for positron emission tomographic studies of the dopamine receptor.
abstract: The ligands currently used for PET studies of the dopamine receptor are fluorine-18-labeled spiperone (FSp) and carbon-11 or fluorine-18-labeled N-methyl-spiperone. All three of these ligands have drawbacks in either their chemical preparation or their biological behavior. We have previously prepared a series of N-fluoroalkyl-spiperone derivatives which are simple to prepare in high radiochemical yield. N-[18F]fluoropropyl-spiperone (3-F-Pr-Sp) and N-[18F]fluoroethyl-spiperone (2-F-Et-Sp) were the most promising ligands. In vitro competitive binding studies showed affinities for the dopamine receptor of 3-F-Pr-Sp greater than FSp greater than 2-F-Et-Sp. Brain extraction studies in a primate model showed that FSp, 2-F-Et-Sp, and 3-F-Pr-Sp were not completely extracted by the brain. High bone uptake and kidney clearance was observed with 3-F-Pr-Sp, while 2-F-Et-Sp cleared through the intestine in rats. This is in contrast to FSp where clearance is through the kidney. Studies to evaluate the extraction of metabolites in the brain were carried out by administering large doses (10 mCi) of FSp, 2-F-Et-Sp and 3-F-Pr-Sp to rats and reinjecting the metabolites in blood into other rats. These experiments showed that less than 0.02% of the metabolites from FSp and 3-F-Pr-Sp entered the brain, while 0.5% of the metabolites from 2-F-Et-Sp entered the brain. The majority of the activity present in the cerebellum after the administration of 2-F-Et-Sp is metabolites; therefore 2-F-Et-Sp is unsuitable for PET imaging studies. PET imaging studies in baboons and in one normal human volunteer with 3-F-Pr-Sp showed a high striatum-to-cerebellum ratio, showing that 3-F-Pr-Sp can replace ligands currently in use to study dopamine receptors.
authors.affiliation: Division of Radiation Sciences, Washington University School of Medicine, St Louis, MO 63110.
authors.forename: M J
authors.initials: MJ
authors.lastname: Welch
authors.forename: J A
authors.initials: JA
authors.lastname: Katzenellenbogen
authors.forename: C J
authors.initials: CJ
authors.lastname: Mathias
authors.forename: J W
authors.initials: JW
authors.lastname: Brodack
authors.forename: K E
authors.initials: KE
authors.lastname: Carlson
authors.forename: D Y
authors.initials: DY
authors.lastname: Chi
authors.forename: C S
authors.initials: CS
authors.lastname: Dence
authors.forename: M R
authors.initials: MR
authors.lastname: Kilbourn
authors.forename: J S
authors.initials: JS
authors.lastname: Perlmutter
authors.forename: M E
authors.initials: ME
authors.lastname: Raichle
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism; D005260:Female; D006801:Humans; D010215:Papio; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000032:analysis*; D013134:Spiperone / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D014055:Tomography, Emission-Computed
chemical_list: D011954:Receptors, Dopamine; C053125:N-(3-fluoropropyl)spiroperidol; D013134:Spiperone